NCT01149915 - Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions

Acute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaChronic Myelogenous LeukemiaHigh-risk Myelodysplastic SyndromeChronic Lymphocytic LeukemiaAdvanced Myelofibrosis

Interventions

DRUG

TH-302

TH-302 will be administered as a 30-minute intravenous infusion daily for 5 days every 21 days. Patients who successfully complete a 3-week treatment cycle without evidence of significant treatment-related toxicity or clinically significant progressive disease will continue to receive treatment for up to six cycles.

Trial Locations (1)

77030

University of Texas M.D. Anderson Cancer Center, Houston